Roche has lost the fast track status it won for the EU marketing application it filed with the European Medicines Agency last October for satralizumab, the drug it is developing to treat the rare disease neuromyelitis optica spectrum disorder (NMOSD).
The EMA decided that the marketing authorization application (MAA) no longer merited accelerated assessment because a rival product had received...








